Improving hearing tests for infants with hearing loss using brain imaging

Improving Early Intervention in Hearing Impaired Children Using Functional Near-Infrared Spectroscopy (fNIRS)

Not applicable Interventional The Bionics Institute of Australia · NCT05847426

This study tests if a new brain imaging technique can help audiologists make better decisions for infants with hearing loss while also checking if parents find the testing comfortable and acceptable.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment40 (estimated)
Ages24 Years and up
SexAll
SponsorThe Bionics Institute of Australia Academic / other
Locations5 sites (East Melbourne, Victoria and 4 other locations)
Trial IDNCT05847426 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to determine if functional near-infrared spectroscopy (fNIRS) can enhance the decision-making process for audiologists treating infants with hearing loss. By providing additional brain activity information alongside standard audiological test results, the study seeks to improve early intervention strategies for affected infants. A pool of experienced audiologists will evaluate the fNIRS results to make more informed management decisions at critical points in the hearing care pathway. The trial will also assess the comfort and acceptability of the fNIRS testing experience for parents and caregivers.

Who should consider this trial

Good fit: Ideal candidates for this study are infants aged 1 to 24 months diagnosed with permanent hearing loss in one or both ears.

Not a fit: Patients who do not have permanent hearing loss or are outside the age range of 1 to 24 months may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to faster and more effective interventions for infants with hearing loss, significantly improving their speech and language development.

How similar studies have performed: While the use of fNIRS in audiology is relatively novel, similar studies in other fields have shown promising results in enhancing diagnostic capabilities.

Eligibility criteria

Show full inclusion / exclusion criteria
The above eligibility applies to the participating audiologists who are in the experimental and control arms of the study

Audiologist Inclusion Criteria:

* Is a qualified audiologist who meets the criteria for membership of Audiology Australia.
* Has at least 1 year of experience in paediatric diagnostic, hearing aid or cochlear implant audiology service provision in Australia.
* Provides a signed and dated informed consent form.

Audiologist Exclusion criteria (only for a specific infant test result):

* Is the managing audiologist for the infant who's results are being provided.

Infants are also recruited into the study to have an fNIRS assessment performed. They do not participate further after the fNIRS test.

Infant Inclusion criteria:

* Between the ages of 1 and 24 months at the time of fNIRS testing.
* Has permanent hearing loss in one or both ears as determined by audiological diagnostic testing.
* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.

Infant Exclusion Criteria:

* There are no exclusion criteria other than not meeting the inclusion criteria.

Where this trial is running

East Melbourne, Victoria and 4 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Hearing ImpairmentInfantsEarly interventionfunctional near-infrared spectroscopy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.